Skip to content

Trial Summary

The primary objective of this study is to assess the objective response rate (ORR) of sacituzumab govitecan-hziy in adult participants with metastatic solid tumors.



ACTRN/NCT /ethics:


Scientific title:

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Sponsor / Cooperative group:

Gilead Sciences

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2019-10-15
Anticipated End Date2023-07-01

Participating Hospitals

HospitalLyell McEwin hospital
Clinical Trial CoordinatorAndy Phay
Phone08 8282 0833
Principal InvestigatorDr Chris Hocking
Recruitment StatusRecruiting